PROJECT SUMMARY

According to World Health Organization (WHO), by 2050, deaths from infections of multidrug-resistant bacteria and viruses to antibiotics will exceed those of cancer. As part of related studies conducted/sponsored by the WHO, some of the findings seem to indicate that 80% of infections are transmitted by contact.

The unfortunate health crisis caused by Covid-19 has made extremely evident that innovative and scalable solutions are not available, in large scale, to mitigate the impact of viruses and bacteria on human beings. Covid-19 has also made evident the asymmetry and/or inequality among the general population regarding protection against viruses and health issues. Low-income people are the most exposed since cannot afford measures as those taken by higher socio-economic segments of the population. Currently, there are very few technologies, globally available, incorporated as part of products of mass consumption (as is the case of the Company's formula) that can help preventing and diminish the transmission and expansion of viruses through human contact and help reduce the spread of virus and bacteria to prevent diseases and protect society.

The Company ("Copptech") is a biotech company, founded and incorporated in Chile, with regional and global sales that has more than 12 years of experience (and 6 registered patents worldwide) in developing solutions that eliminate bacteria, viruses and fungi. COPPTECH's patented technology consists of a scientifically balanced combination of copper and zinc that can be incorporated in the manufacturing of different materials such as textiles, polymers, non-woven, cellulose, wood, and metals. Both compounds have widely proven biocidal properties against bacteria, fungi, viruses and mites.

Copptech's patent is registered with the US-Environmental Protection Agency (EPA) with an approved Tier-I product protection claim which enables the Company to integrate their antimicrobial formula into products to provide them with protection against bacteria, mold, and fungi.

The objective of this project is to support Copptech (a highly scalable, innovative, environmentally conscious VC-backed company) expanding its LAC operations and becoming the leading antimicrobial ingredient brand in LAC and the world, whose trusted product is recognized as a superior, efficient and low-cost antimicrobial formula. The Company's product will provide well-being without limits to all segments of society, including the low-income segments of society who tend to be more affected (economically and health wise) by daily exposure to and contact with potentially infected materials and surfaces.

IDB Lab would provide to the Company a medium-term revenues-based loan (of up to USD1,500,000)[1] that is adapted to its specific financial needs and business plans. For the Company, this instrument provides financial flexibility as payments will reflect the pattern of its revenues. Moreover, this method is well suited for the Company which has a Business-to-Business business model that can produce relatively high margins given its license-based revenue model. An additional benefit to the Company is that this method of financing is non-dilutive.

Aurus Capital (Chile), via its Aurus Ventures III, is one of the Company's shareholders (12.28%) and recently injected $2 Million into the Company. IDB Lab has a long history, as investor of Aurus Capital which has shown a strong track record in investments in innovative companies in the sector of Industrial Tech.

[1] The Loan would be disbursed in two (2) tranches at the most. The first one for USD750,000 and the second one for up to USD750,00 subject to the Company complying with a set of conditions precedent.